Partner Therapeutics

Stories

FDA approves Bizengri as first targeted drug for rare NRG1-driven bile duct cancer

As of May 2026: Drug sponsor and U.S. commercial lead for Bizengri

Patients with advanced bile duct cancer driven by a rare genetic fusion called NRG1 had nothing approved for them after chemotherapy failed. On May 8, the FDA approved Bizengri (zenocutuzumab-zbco) from Partner Therapeutics as the first drug targeting this NRG1 fusion, blocking the abnormal protein it produces, which fuels tumor growth.

Updated May 31